ArticleEcancermedicalscience2022

A single-arm feasibility phase II study of EMF (erlotinib + methotrexate + 5-fluorouracil) regimen in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Annie Kanchan Baa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.